Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Nov

01

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

Read More Share:linkedin| twitter| email

Oct

31

NAYZILAM® (midazolam) Results Published in Epilepsy & Behavior Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Read More Share:linkedin| twitter| email

Oct

18

Evolving Expectations for Dermatological Conditions

Read More Share:linkedin| twitter| email

Oct

13

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Read More Share:linkedin| twitter| email

Oct

12

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Read More Share:linkedin| twitter| email

Oct

04

UCB presents late-breaking posters at Child Neurology Society Meeting

Read More Share:linkedin| twitter| email

Aug

01

Evolving Expectations for Dermatological Conditions

Read More Share:linkedin| twitter| email

Jul

21

UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

Read More Share:linkedin| twitter| email

Jun

27

Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

Read More Share:linkedin| twitter| email

Jun

27

UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)